search
Back to results

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

Primary Purpose

Anemia

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Ferric Carboxymaltose
Standard Medical Care (SMC)
Sponsored by
American Regent, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Anemia

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or Female 18 to 85 years of age
  • NDD-CKD Patients
  • TSAT </= 25%
  • Hgb </= 11.5
  • Ferritin </= 300
  • HD-CKD Patients
  • TSAT </= 30%
  • Hgb </= 12
  • Ferritin </= 500

Exclusion Criteria:

  • Previous participation in a FCM trial
  • Known Hypersensitivity to FCM
  • History of anemia other that anemia due to chronic renal failure
  • Current history of GI bleeding
  • Received IV Iron within the last 30 Days
  • Anticipated need for surgery
  • Malignancy history
  • AST or ALT greater than normal
  • Received an investigational drug within 30 days of screening
  • Pregnant or sexually active females who are not willing to use an effective form of birth control

Sites / Locations

  • Luitpold Pharmaceuticals

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Ferric Carboxymaltose (FCM)

Standard Medical Care (SMC)

Arm Description

Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.

SMC for IDA (as determined by the Investigator) for treating CKD related anemia.

Outcomes

Primary Outcome Measures

Incidence of Treatment-emergent Serious Adverse Events (SAE's)

Secondary Outcome Measures

Full Information

First Posted
October 22, 2007
Last Updated
January 22, 2018
Sponsor
American Regent, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT00548691
Brief Title
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Official Title
A Multi-center, Randomized Controlled Study to Investigate the Safety and Tolerability of IV Ferric Carboxymaltose (FCM) vs Standard Medical Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
Study Type
Interventional

2. Study Status

Record Verification Date
January 2018
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
January 2009 (Actual)
Study Completion Date
July 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
American Regent, Inc.

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
513 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Ferric Carboxymaltose (FCM)
Arm Type
Experimental
Arm Description
Subjects received an undiluted dose of iron as FCM IV (15 mg/kg up to a maximum of 1000 mg) or subjects received 200 mg of FCM IV push undiluted directly into the venous line of the dialyzer.
Arm Title
Standard Medical Care (SMC)
Arm Type
Active Comparator
Arm Description
SMC for IDA (as determined by the Investigator) for treating CKD related anemia.
Intervention Type
Drug
Intervention Name(s)
Ferric Carboxymaltose
Intervention Type
Drug
Intervention Name(s)
Standard Medical Care (SMC)
Primary Outcome Measure Information:
Title
Incidence of Treatment-emergent Serious Adverse Events (SAE's)
Time Frame
from Day 0 through 30 days after the last dose of study drug

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or Female 18 to 85 years of age NDD-CKD Patients TSAT </= 25% Hgb </= 11.5 Ferritin </= 300 HD-CKD Patients TSAT </= 30% Hgb </= 12 Ferritin </= 500 Exclusion Criteria: Previous participation in a FCM trial Known Hypersensitivity to FCM History of anemia other that anemia due to chronic renal failure Current history of GI bleeding Received IV Iron within the last 30 Days Anticipated need for surgery Malignancy history AST or ALT greater than normal Received an investigational drug within 30 days of screening Pregnant or sexually active females who are not willing to use an effective form of birth control
Facility Information:
Facility Name
Luitpold Pharmaceuticals
City
Norristown
State/Province
Pennsylvania
ZIP/Postal Code
19403
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients

We'll reach out to this number within 24 hrs